9.12.00

Attorney Docket No.: 5956.200-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

Express Mail Label No. <u>EL636740265US</u> Date of Deposit <u>September 11, 2000</u>

Sir:

This is a request for filing an application under 37 C.F.R. 1.53(b) of

Applicant(s): Andersen et al.

Title: Modulators of Protein Tyrosine Phosphatases (PTPases)

142 pages of specification <u>0</u> sheets of Formal Drawings

4 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:

Total Claims:  $74 - 20 = 54 \times 18 = $972.00$ 

Independent Claims:  $1 - 3 = 0 \times 78 = $0$ 

Total Fee:

\$1662.00

\$690.00

Priority of Danish application no. PA 1999 01278 filed on September 10, 1999 is claimed under 35 U.S.C. 119. A certified copy will follow.

Priority of U.S. provisional application no. 60/156,586 filed on September 29, 1999 is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$1662, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 11, 2000

Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



Attorney Docket No.: 5956.200-US

09-12-06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**PATEN** 

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application for

Title: Modulators of Protein Tyrosine Phosphatases (PTPases)

EXPRESS MAIL CERTIFICATE

Applicants: Andersen et al.

Sir:

Express Mail Label No. EL636740265US

Date of Deposit: September 11, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)

2. Patent Application

3. Unexecuted Combined Declaration and Power of Attorney

4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Gina Maldonado

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123